Patrick Daly

DocwireNews

In a presentation at the 2022 American Society of Clinical Oncology Annual Meeting, Prithviraj Bose and colleagues reported that mutations in splicing factor 3B subunit 1 (SF3B1) are an uncommon occurrence in patients with myelofibrosis and do not appear to substantially affect outcomes and disease phenotype.This finding is distinct from the effects of SF3B1 mutations in other myelodysplastic syndromes and myeloproliferative neoplasms, where they indicate a &ldquo;unique phenotype&rdquo; with a favorable prognosis, according to Dr. Bose.The study retrospectively analyzed 381 patients with World Health Organization (WHO)-defined myelofibrosis who visited the authors&rsquo; center from January 2017 to July 2021. Patients with either SF3B1-mutated or SF3B1-wild type myelofibrosis were compared on the following variables: disease phenotype, myeloproliferative neoplasms driver and co-occurring mutations, cytogenetics, dynamic International Prognostic Scoring System (IPSS) score, transfusion requirements, treatment characteristics, and survival outcomes.Of the 381 patients, 29 (8%) were SF3B1-mutated, with K666N being the most common mutation (52%). Overall frequencies of JAK2, CALR, MPL mutations, and triple negative myelofibrosis were similar between the SF3B1-mutated and non-mutated groups. Notably, more SF3B1-mutated patients were PRBC transfusion-dependent at presentation that non-mutated patients.Ultimately, the authors concluded that SF3B1 mutations are rare in patients with myelofibrosis and, except for PRBC transfusion dependence, most measures between mutated and non-mutated groups were relatively similar.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Splicing Factor 3B Subunit 1 Mutations in Myelofibrosis

ASCO 2022

In a presentation at the 2022 American Society of Clinical Oncology Annual Meeting, Prithviraj Bose and colleagues reported that mutations in splicing factor 3B subunit 1 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe